Compare Amylx Pharmaceuticals Inc (AMLX) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs PepsiCo, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while PepsiCo, Inc. trades at $137.85 (market cap $187.51B). The key difference: PepsiCo, Inc. is far larger — about 94.7× Amylx Pharmaceuticals Inc's market cap, and PepsiCo, Inc. pays a 4.31% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | PEP | |
|---|---|---|
Market Cap | $1.98B | $187.51B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $170.44 |
52-Week Low | $7.64 | $133.81 |
Enterprise Value | $1.70B | $230.01B |
Dividend Yield | — | 4.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
PepsiCo (PEP) trades at $137.38, down 0.35% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong profitability with a 10.78% net income margin and 51.59% ROE, though revenue growth is modest. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while the company continues to beat earnings estimates, with Q3 2026 results pending.
The outlook is mixed: analyst consensus is a 'Hold' with a $159.27 price target, implying upside, but technical weakness and competitive pressures pose risks. Investment appeal lies in steady dividends and earnings beats, but margin pressures from pricing strategies and high debt levels require monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
